Ultragenyx Pharmaceutical Inc.

353 articles with Ultragenyx Pharmaceutical Inc.

• Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

  5/17/2022

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA).

• Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

  5/9/2022

  Ultragenyx Pharmaceutical Inc. today announced that clinical, preclinical and manufacturing data from its investigational gene therapy programs will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th  Annual Meeting, which will be held both in person and virtually May 16-19, 2022.

• Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

  5/5/2022

  Ultragenyx Pharmaceutical Inc. reported its financial results for the quarter ended March 31, 2022 and reaffirmed its financial guidance for the year.

• Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

  5/3/2022

  Ultragenyx Pharmaceutical Inc. announced that Camille Bedrosian, M.D., the company’s Chief Medical Officer, and Mardi Dier, the company’s Chief Financial Officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:40 PM ET.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2022

  5/3/2022

  Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 20,480 shares of common stock of the company and 11,620 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.

• Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

  4/27/2022

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 5:00pm ET to discuss its financial results and corporate update for the quarter ended March 31, 2022.

• 

  Clinical Catch-Up: COVID-19 Updates from Sinovac, Moderna, Arcturus, Novavax and More

  4/25/2022

  It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.

• Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directorse

  4/22/2022

  Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced the appointment of Amrit Ray, M.D., M.B.A. to the company’s Board of Directors.

• 

  Ultragenyx, Mereo Embark on Key Osteogenesis Imperfecta Trial

  4/21/2022

  Ultragenyx and Mereo celebrated their first patient dosed in a Phase II/III study investigating the use of setrusumab as a treatment for osteogenesis imperfecta (OI).

• Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

  4/20/2022

  Ultragenyx Pharmaceutical Inc. today announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients ages 5 to <26 years of age.

• 

  Medical Advocacy and Ingenuity of the Human Spirit are Curing Disease

  3/31/2022

  When Sekar Kathiresan's brother unexpectedly died from a heart attack, he changed the course of his life to found a company with a novel medicine that may prevent them.

• Ultragenyx to Participate in the Cowen Health Care Conference

  3/2/2022

  Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:10 PM ET.

• 

  Five Top CEOs to Watch in 2022

  2/23/2022

  Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.

• Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

  2/10/2022

  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2021 and reaffirmed its financial guidance for 2022.

• Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

  2/3/2022

  Ultragenyx Pharmaceutical Inc. today announced that it will host a conference call on Thursday, February 10, 2022, at 5:00 pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2021.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 02, 2022

  2/2/2022

  Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 16,050 shares of common stock of the company and 5,350 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.

• 

  UConn & UltraGenyx Report Life-Changing Results in Glycogen Storage Disease

  1/21/2022

  ​The Glycogen Storage Disease Program at Connecticut Children's and UConn Health reported success in a Phase I/II trial of a gene therapy for GSD-Ia.

• Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones

  1/10/2022

  Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2021 Crysvita® revenue in Ultragenyx territories and Dojolvi® global revenue, cash and investments at year end 2021, and provided 2022 revenue guidance for Crysvita in Ultragenyx territories and Dojolvi globally.

• Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States

  1/7/2022

  Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultra-rare inherited form of high cholesterol.

• Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

  1/6/2022

  Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the H.C. Wainwright BioConnect Conference on Thursday, January 13, 2022 at 7:00 AM ET.